Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Recruiting Phase 3 Interventional

Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)

ClinicalTrials.gov ID: NCT06961214

Public ClinicalTrials.gov record NCT06961214. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 29, 2026, 3:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study of the Efficacy and Safety of Depemokimab in Adult Participants With COPD With Type 2 Inflammation

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Depemokimab is being developed as a treatment for individuals with moderate to severe COPD. The aim of this study is to assess the efficacy and safety of depemokimab compared as an add-on medicine in participants with uncontrolled moderate to severe COPD with type 2 inflammation.

Study identification

NCT ID
NCT06961214
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
960 participants

Conditions and interventions

Eligibility (public fields only)

Age range
40 Years to 80 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 22, 2025
Primary completion
Aug 20, 2029
Completion
Aug 20, 2029
Last update posted
Apr 8, 2026

2025 – 2029

United States locations

U.S. sites
54
U.S. states
19
U.S. cities
49
Facility City State ZIP Site status
GSK Investigational Site Sheffield Alabama 35660 Recruiting
GSK Investigational Site Aurora Colorado 80012 Recruiting
GSK Investigational Site Brooksville Florida 346135 Recruiting
GSK Investigational Site Doral Florida 33172 Recruiting
GSK Investigational Site Fort Lauderdale Florida 33316 Recruiting
GSK Investigational Site Miami Florida 33122 Recruiting
GSK Investigational Site Miami Florida 33125 Recruiting
GSK Investigational Site Miami Florida 33155 Recruiting
GSK Investigational Site Miami Florida 33165 Recruiting
GSK Investigational Site Miami Florida 33175 Recruiting
GSK Investigational Site Miami Florida 33176 Recruiting
GSK Investigational Site Miami Lakes Florida 33016 Recruiting
GSK Investigational Site Naples Florida 34102 Recruiting
GSK Investigational Site New Port Richey Florida 34653 Recruiting
GSK Investigational Site Ocala Florida 34471 Recruiting
GSK Investigational Site Orlando Florida 32825 Recruiting
GSK Investigational Site Ormond Beach Florida 32174 Recruiting
GSK Investigational Site Palmetto Bay Florida 33157 Recruiting
GSK Investigational Site St. Petersburg Florida 33704 Recruiting
GSK Investigational Site Adairsville Georgia 30103 Recruiting
GSK Investigational Site Cordele Georgia 31015 Recruiting
GSK Investigational Site East Point Georgia 30344 Recruiting
GSK Investigational Site Morrow Georgia 30260 Recruiting
GSK Investigational Site Boise Idaho 83702 Recruiting
GSK Investigational Site Chicago Illinois 60608 Recruiting
GSK Investigational Site Baton Rouge Louisiana 70816 Recruiting
GSK Investigational Site Lafayette Louisiana 70506 Recruiting
GSK Investigational Site Shreveport Louisiana 71105 Recruiting
GSK Investigational Site Bangor Maine 04401 Recruiting
GSK Investigational Site Rockville Maryland 20854 Recruiting
GSK Investigational Site Allen Park Michigan 48101 Recruiting
GSK Investigational Site Detroit Michigan 48202 Recruiting
GSK Investigational Site Garden City Michigan 48135 Recruiting
GSK Investigational Site Troy Michigan 48085 Recruiting
GSK Investigational Site Las Vegas Nevada 89144 Recruiting
GSK Investigational Site Moorestown New Jersey 08057 Recruiting
GSK Investigational Site Sewell New Jersey 08080 Recruiting
GSK Investigational Site Mount Kisco New York 10549 Recruiting
GSK Investigational Site New Windsor New York 12553 Recruiting
GSK Investigational Site Shelby North Carolina 28152 Recruiting
GSK Investigational Site DuBois Pennsylvania 15801 Recruiting
GSK Investigational Site Philadelphia Pennsylvania 19140 Recruiting
GSK Investigational Site Spartanburg South Carolina 29303 Recruiting
GSK Investigational Site Union South Carolina 29379 Recruiting
GSK Investigational Site Knoxville Tennessee 37919 Recruiting
GSK Investigational Site Austin Texas 78744 Recruiting
GSK Investigational Site Dallas Texas 75254 Recruiting
GSK Investigational Site El Paso Texas 79902-1123 Recruiting
GSK Investigational Site Houston Texas 77094 Recruiting
GSK Investigational Site Lampasas Texas 76550 Recruiting
GSK Investigational Site Richmond Texas 77407 Recruiting
GSK Investigational Site San Antonio Texas 78229 Recruiting
GSK Investigational Site Webster Texas 77598 Recruiting
GSK Investigational Site Morgantown West Virginia 26505-0423 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 100 non-U.S. sites.

Recently updated Pulmonary Disease, Chronic Obstructive trials

Other public records listing Pulmonary Disease, Chronic Obstructive. Sorted by last update posted; newest first. Not a recommendation.

All Pulmonary Disease, Chronic Obstructive trials →

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06961214, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 8, 2026 · Synced Jul 29, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06961214 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →